Drug
Darbepoetin Alfa
Darbepoetin Alfa: highest development phase Phase 3, developed by Amgen, Kyowa Kirin, United Therapeutics. 6 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Amgen, Kyowa Kirin, United Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| Darbepoetin alfa NCT01652872 | Phase 3 | Anemia in Chronic Kidney Disease Patients Not on Dialysis |
| darbepoetin alfa NCT00070382 | Phase 3 | Anemia |
| darbepoetin alfa NCT00344409 | Phase 3 | Anemia |
| Darbepoetin Alfa NCT00120692 | Phase 2 | Breast Cancer |
| darbepoetin alfa NCT00359840 | Phase 2 | Anemia |
| Darbepoetin alfa NCT00355407 | Not Applicable | Hematologic Malignancies |
Latest
No recent events.
Follow Darbepoetin Alfa on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.